Pneumonia Direct Pilot

Active, not recruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

July 3, 2025

Study Completion Date

December 30, 2025

Conditions
Pneumonia, BacterialVentilator Associated Pneumonia
Interventions
DIAGNOSTIC_TEST

Pathogen and Host Directed testing

"This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository."

Trial Locations (4)

15213

University of Pittsburgh Medical Center, Pittsburgh

48073

Corewell (William Beaumont), Royal Oak

48202

Henry Ford Hospital, Detroit

63110

Washington University School of Medicine in St. Louis, St Louis

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Duke University

OTHER

NCT06181669 - Pneumonia Direct Pilot | Biotech Hunter | Biotech Hunter